Genprex Inc Stock Price, News & Analysis

Genprex (NASDAQ: GNPX) will present the trial design of its Acclaim-3 Phase 1/2 clinical trial at the 2025 ASCO Annual Meeting. The trial evaluates Reqorsa® Gene Therapy in combination with Tecentriq® as maintenance therapy for extensive stage small cell lung cancer (ES-SCLC). The study aims to improve the current median progression-free survival of 2.6 months in ES-SCLC patients. The trial's Phase 2 portion, which began enrollment in December 2024, will include 50 patients and targets a median PFS of approximately 4.3 months. The presentation will take place on May 31, 2025, featuring research showing that TUSC2, a tumor suppressor gene, is decreased in 100% of SCLC patients and absent in 41% of cases. Preclinical studies demonstrated that the Reqorsa-Tecentriq combination significantly increased tumor cell killing compared to Tecentriq alone.

Genprex (NASDAQ: GNPX) presented positive preclinical data for GPX-002, its diabetes gene therapy drug candidate, at the ASGCT 28th Annual Meeting. The therapy uses recombinant adeno-associated virus (rAAV) to deliver Pdx1 and MafA genes, converting alpha cells into insulin-secreting beta-like cells. Studies in Non-Human Primates (NHPs) showed that one month post-infusion, subjects demonstrated improved glucose tolerance and reduced insulin requirements. The research revealed that temporary immunosuppression using rituximab, rapamycin, and steroids effectively prevents anti-viral immunity, though longer immunosuppression may be needed. The company continues preclinical studies in both Type 1 and Type 2 diabetes NHP models, evaluating viral efficacy after six months of immunosuppression.

Genprex (NASDAQ: GNPX) has signed a new Sponsored Research Agreement (SRA) with the University of Pittsburgh to study GPX-002, its gene therapy treatment for Type 1 (T1D) and Type 2 diabetes (T2D) in animal models. Previous preclinical data showed statistically significant improvements in insulin requirements, c-peptide levels, and glucose tolerance. GPX-002 uses an AAV vector containing Pdx1 and MafA genes administered into the pancreatic duct. In T1D, it transforms alpha cells into functional beta-like cells that produce insulin while potentially evading immune response. For T2D, the therapy aims to rejuvenate exhausted beta cells. The treatment can be administered in humans through routine endoscopy.

Genprex (NASDAQ: GNPX) has secured an exclusive patent license agreement with UTHealth Houston for its lead drug candidate, Reqorsa® Gene Therapy, targeting glioblastoma treatment. The agreement grants Genprex exclusive commercial rights and patent exclusivity for using REQORSA in treating glioblastoma, the most aggressive and common primary brain tumor in adults. The company previously reported positive preclinical data in October 2024, where researchers observed that REQORSA significantly reduced glioblastoma cell viability and suppressed cell migration. The treatment works by restoring TUSC2 expression, which has been identified as a novel tumor suppressor for glioblastoma. These promising in vitro results support further evaluation using mouse models.

Genprex announced positive preclinical data for their Reqorsa® Gene Therapy in treating Ras inhibitor resistant lung cancer at the 2025 AACR Annual Meeting in Chicago. The research focused on treating KRASG12C mutant non-small cell lung cancer (NSCLC).

Key findings showed that Reqorsa effectively overcomes resistance to LUMAKRAS® (sotorasib) in NSCLC mouse models. The therapy demonstrated significant results both alone and in combination with sotorasib:

• Reduced colony formation and increased cancer cell death in resistant cell lines
• Decreased viability of resistant organoids
• Showed strong anti-tumor effects in controlling tumor growth
• Achieved synergistic anti-tumor effects when combined with sotorasib

The research suggests Reqorsa's potential as a treatment for Ras inhibitor resistant lung cancer, either as a standalone therapy or in combination with Ras inhibitors.

Genprex announced that its research collaborators will present positive preclinical data for their diabetes gene therapy drug candidate GPX-002 at the ASGCT 28th Annual Meeting in New Orleans this May.

The research focuses on a novel gene therapy using recombinant adeno-associated virus (rAAV) to treat diabetes mellitus. Key findings show that retrograde intraductal infusion of rAAV6 successfully delivered Pdx1 and MafA genes, converting alpha cells into insulin-secreting beta-like cells.

Testing on non-human primates demonstrated:

• Improved glucose tolerance and reduced insulin needs one month post-infusion
• Durable effects using AAV6 capsid with endocrine-specific promoters
• Successful immune response management using temporary immunosuppression
• Sustained therapeutic effects even after stopping immunosuppression

The research represents a potential breakthrough in diabetes treatment, with results showing sustained therapeutic effects without long-term immunosuppression requirements.

Genprex (NASDAQ: GNPX) has signed an exclusive patent license agreement with NYU Langone Health for Reqorsa® Gene Therapy to treat mesothelioma. The therapy shows promising preclinical results in treating Malignant Pleural Mesothelioma (MPM).

Research data presented at the 2024 EORTC-NCI-AACR Symposium demonstrated that REQORSA significantly decreased cell proliferation and invasion while increasing cell apoptosis in MPM cell lines. The therapy utilizes the TUSC2 tumor suppressor gene, which is downregulated in 84% of mesotheliomas.

Genprex formed a Mesothelioma Clinical Advisory Board in 2024 with four leading researchers to support its preclinical program. According to CDC data, mesothelioma affects approximately 3,000 new cases annually in the U.S., with a life expectancy of 18 months and a 3-year survival rate of 23% with treatment.

Genprex (NASDAQ: GNPX) has been selected to present at the 2025 ASCO Annual Meeting in Chicago, showcasing their Acclaim-3 Phase 1/2 clinical trial design. The presentation will focus on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® as maintenance therapy for extensive stage small cell lung cancer (ES-SCLC).

The presentation is scheduled for May 31, 2025, from 1:30 to 4:30 p.m. CT, and will be delivered by Dr. Bo Wang from Oncology Associates of Oregon. The abstract will be featured in the Trials in Progress poster session, highlighting the company's innovative approach in cancer treatment development.

Genprex (NASDAQ: GNPX) announced the publication of their research collaborators' abstract in Cancer Research's online Proceedings supplement. The abstract, which will be presented at the 2025 AACR Annual Meeting, showcases positive preclinical data for Reqorsa® Gene Therapy in treating KRASG12C mutant non-small cell lung cancer (NSCLC).

The research demonstrates that TUSC2 gene therapy (REQORSA) effectively overcomes sotorasib acquired resistance in KRASG12C mutant NSCLC mouse xenografts. Key findings show that TUSC2 transfection reduced colony formation in resistant cell lines, increased apoptosis, and decreased organoid viability. The treatment showed significant antitumor efficacy, particularly when combined with sotorasib in resistant tumors.